District of Delaware: IPR Estoppel Does Not Apply to Prior-Art Products

Jul 29, 2022

Reading Time : 2 min

The court initially noted that it was undisputed that the defendant could not have raised the prior-art products during a related IPR proceeding. However, the patentee had argued that the prior-art products at issue in the district court case were “cumulative” to the paper-based prior art that the defendant had asserted in the IPR proceeding. As such, the patentee argued that the defendant was still estopped from pursuing invalidity defenses based on the products. The court explained that although it had agreed to hear evidence on the cumulativeness of the prior-art products, the dispute could be settled without a hearing.

The court resolved the dispute by looking at the text of the estoppel statute and using “well-accepted canons of construction.” The court first explained that by the plain text of the statute, estoppel only applies to grounds that were raised or reasonably could have been raised during the IPR proceeding. Furthermore, even though the term “ground” was not defined in the statute, other courts had interpreted it to mean the “specific pieces of prior art” involved in the challenge. Adopting the same interpretation, the court reasoned that because prior-art products cannot not be raised in an IPR, such products cannot not be a “ground” that is subject to statutory estoppel.

The court acknowledged that the issue is not settled. Across the country, judges have reached varying conclusions, including a decision in which the former Chief Judge of the District of Delaware ruled that Section 315(e)(2) estoppel did apply to a prior-art product, given the circumstances of that case. Nevertheless, the court reasoned that adhering closely to the statutory text was the most appropriate course given that neither the Supreme Court nor the Federal Circuit has decided the issue.

The court also explained that Congress had chosen the statutory text after “considered debate and careful thought.” And because Congress could have provided broader categories of estoppel but did not do so, the court should not seek to create additional bases for estoppel.

Practice tip:

This decision highlights an on-going struggle among district courts about the scope of IPR estoppel. Until the scope is clarified, at least in the first instance by the Federal Circuit, parties should consider carefully whether estoppel might apply to invalidity grounds premised on prior-art products. Parties should look to decisions from within the district court and, more specifically, the presiding judge to determine how estoppel has been applied.

Chemours Co. FC LLC v. Daikin Indus., Ltd., 2022 WL 2643517, C.A. No. 17-1612 (MN) (D. Del. July 8, 2022)

Share This Insight

Previous Entries

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

IP Newsflash

January 17, 2025

The District of Arizona recently held that a plaintiff’s failure to mark patented products during the time period that marking was required barred it from recovering all pre-notice damages, including for a period of time when there was no obligation to mark.

...

Read More

IP Newsflash

January 16, 2025

The Unified Patent Court (UPC) aims to provide expeditious decisions for its litigants. That means that there is a higher bar for obtaining extensions of time. As exemplified in BMW v. ITCiCo, the UPC’s reluctance to grant extensions can have serious consequences, including revocation of the patent.

...

Read More

IP Newsflash

January 15, 2025

The Patent Trial and Appeal Board granted institution of inter partes review of a patent directed to delivery of targeted television advertisements. The board rejected patent owner’s argument that a lack of particularity as to the asserted grounds justified denial under 35 U.S.C. § 312(a), holding that “simply including a significant amount of testimony and a number of supporting references is not, by itself, a reason to find that the particularity requirement is not met.”

...

Read More

IP Newsflash

December 2, 2024

The Patent Trial and Appeal Board determined that a reference could be used as prior art because patent owner failed to provide sufficient evidence that the prior art’s disclosure was invented by all four named inventors, and thus the same “inventive entity,” as the challenged claims.

...

Read More

IP Newsflash

December 2, 2024

The Patent Trial and Appeal Board rejected a patent owner’s assertion that petitioner should have named a third party, which was a defendant in a related district court patent infringement litigation and a party to a joint defense agreement (JDA) with petitioner, as a real party-in-interest (RPI). Had the board ruled otherwise and found the third party to be an RPI, the petition would have been time-barred under 35 U.S.C. § 315(b).

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.